Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920

Marko Skelin¹, Dario Rahelić^{2

3}, Petar Skelin⁴, Marko Lucijanic⁵

Affiliations

¹ Department of Pharmacy, General Hospital Šibenik, Šibenik, Croatia marko.skelin@bolnica-sibenik.hr.
² University of Zagreb School of Medicine, Zagreb, Croatia.
³ Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia.
⁴ Faculty of Medicine, Aalborg University, Denmark.
⁵ Department of Hematology, Dubrava University Hospital, Zagreb, Croatia.

Comment

Marko Skelin et al. Diabetes Care. 2020 Feb.

. 2020 Feb;43(2):e28-e29.

doi: 10.2337/dc19-2039.

Marko Skelin¹, Dario Rahelić^{2

3}, Petar Skelin⁴, Marko Lucijanic⁵

¹ Department of Pharmacy, General Hospital Šibenik, Šibenik, Croatia marko.skelin@bolnica-sibenik.hr.
² University of Zagreb School of Medicine, Zagreb, Croatia.
³ Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia.
⁴ Faculty of Medicine, Aalborg University, Denmark.
⁵ Department of Hematology, Dubrava University Hospital, Zagreb, Croatia.

No abstract available

Comment in

Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial.
Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Nauck MA, et al. Diabetes Care. 2019 Oct;42(10):1912-1920. doi: 10.2337/dc19-0415. Epub 2019 Aug 9. Diabetes Care. 2019. PMID: 31399438 Free PMC article. Clinical Trial.